Christopher A. Viehbacher's most recent trade in Biogen Inc was a trade of 15,453 Common Stock done . Disclosure was reported to the exchange on Feb. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 15,453 | 36,548 (0%) | 0% | 0 | Common Stock | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 15,453 | 30,907 | - | - | Restricted Stock Unit | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 9,008 | 25,451 (0%) | 0% | 0 | Common Stock | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 9,008 | 9,009 | - | - | Restricted Stock Unit | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 201.18 per share. | 06 Feb 2026 | 6,624 | 29,924 (0%) | 0% | 201.2 | 1,332,616 | Common Stock |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 201.18 per share. | 06 Feb 2026 | 4,356 | 21,095 (0%) | 0% | 201.2 | 876,340 | Common Stock |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 7,040 | 19,847 (0%) | 0% | 0 | Common Stock | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 7,040 | 0 | - | - | Restricted Stock Unit | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 177.78 per share. | 01 Dec 2025 | 3,404 | 16,443 (0%) | 0% | 177.8 | 605,163 | Common Stock |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 46,360 | 46,360 | - | - | Restricted Stock Unit | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 9,008 | 18,017 | - | - | Restricted Stock Unit | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 9,008 | 16,008 (0%) | 0% | 0 | Common Stock | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 06 Feb 2025 | 3,201 | 12,807 (0%) | 0% | 141.3 | 452,461 | Common Stock |
| Biogen | Viehbacher Christopher A. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 27,025 | 27,025 | - | - | Restricted Stock Unit | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 80,522 | 80,522 | - | - | Stock Option | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 45,998 | 45,998 | - | - | Performance Stock Unit | |
| Biogen | Christopher A. Viehbacher | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 7,040 | 7,040 | - | - | Restricted Stock Unit |